Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.53 |
| ▸ | KLK7 | P49862 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 7/20 | 0.46 |
| ▸ | CTSL | P07711 | 6/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14337550 | 0.84 | MAPT (0.51) | KLK5CTSKCTSLCTSSCTSB | |
| SCHEMBL10450036 | 0.83 | HSD11B1 (0.52) | CA1CTSKCTSLCTSBL3MBTL1 | |
| SCHEMBL10320596 | 0.83 | HSD11B1 (0.52) | CA1CTSKCTSLCTSBL3MBTL1 | |
| SCHEMBL27345269 | 0.83 | HSD11B1 (0.52) | CA1CTSKCTSLCTSBL3MBTL1 | |
| SCHEMBL19716705 | 0.82 | KLK5 (0.57) | KLK5KLK7CTSKCTSSL3MBTL1 | |
| SCHEMBL16011173 | 0.82 | KLK5 (0.57) | KLK5KLK7CTSKCTSSL3MBTL1 | |
| SCHEMBL30889534 | 0.81 | KLK5 (0.53) | KLK5KLK7CA1CTSKCTSL | |
| SCHEMBL3743386 | 0.81 | KLK5 (0.52) | KLK5KLK7CA1CTSKCTSL | |
| SCHEMBL3743382 | 0.81 | KLK5 (0.52) | KLK5KLK7CA1CTSKCTSL | |
| SCHEMBL1841225 | 0.79 | KLK5 (0.52) | KLK5KLK7CA1CTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288563-B2 | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-30 | — | — | US | disclosed |
| US-20050192276-A1 | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192276-A1 | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity | CCR1, CCR2, BDKRB1 | KLK5 2952/4885KLK7 2387/4885CA1 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.